Activation of the intrinsic apoptosis pathway contributes to the induction of apoptosis in hepatocellular carcinoma cells by valproic acid

Oncology Letters

Volumn 9, Issue 2, 2015, Pages 881-886

  Yang, Weihua ^a   Zhao, Xia ^a,b   Pei, Fengyan ^a   Ji, Mingyu ^a   Ma, Wanshan ^b   Wang, Yunshan ^a   Jiang, Guosheng ^c  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Hepatocellular carcinoma; Histone deacetylase inhibitor; Valproic acid

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; CYCLIN A; CYCLIN D1; CYCLIN E; CYCLIN P21; CYCLINE; HISTONE DEACETYLASE 1; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MRNA EXPRESSION ASSAY; MTT ASSAY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84918826968     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2739     Document Type: Article

References (24)

1. Turner BM: Cellular memory and the histone code. Cell 111: 285-291, 2002.
2. Mottet D and Castronovo V: Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25: 183-189, 2008.
3. Weichert W, Röske A, Gekeler V, et al: Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol 9: 139-148, 2008.
4. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: causes and therapies. Nature 1: 194-202, 2001.
5. Mork CN, Faller DV and Spanjaard RA: A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 11: 1091-1104, 2005.
6. Pan LN, Lu J and Huang B: HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 4: 337-343, 2007.
7. Gallinari P, Di Marco S, Jones P, et al: HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 17: 195-211, 2007.
8. Eyal S, Yagen B, Sobol E, et al: The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45: 737-744, 2004.
9. Chen MS, Li JQ, Zhang YQ, et al: High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 8: 74-78, 2002.
10. Cruft HJ, Mauritzen CM and Stedman E: Abnormal properties of histones from malignant cells. Nature 174: 580-585, 1954.
11. Shi Y, Lan F, Matson C, et al: Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941-953, 2004.
12. Seligson DB, Horvath S, Shi T, et al: Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266, 2005
13. Yang H, Hoshino K, Sanchez-Gonzalez B, et al: Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid. Leuk Res 29: 739-748, 2005.
14. Zhou Q, He Q and Liang LJ: Expression of p27, cyclin E and cyclin A in hepatocellular carcinoma and its clinical significance. World J Gastroenterol 9: 2450-2454, 2003.
15. Catalano MG, Fortunati N, Pugliese M, et al: Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90: 1383-1389, 2005.
16. Buolamwini JK: Cell cycle molecular targets in novel anticancer drug discovery. Curr Pharm Des 6: 379-392, 2000.
17. Tsou MF and Stearns T: Mechanism limiting centrosome duplication to once per cell cycle. Nature 442: 947-951, 2006.
18. Shin JY, Kim HS, Park J, et al: Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 60: 262-265, 2000.
19. Park HY, Kim MK, Moon SI, et al: Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through p53/p21WAF1/CIP1 pathway. Cancer Sci 97: 430-436, 2006.
20. Pulukuri SM and Rao JS: Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells. Int J Oncol 26: 863-871, 2005.
21. Luong QT, O’Kelly J, Braunstein GD, et al: Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12: 5570-5577, 2006.
22. Logue SE and Martin SJ: Caspase activation cascades in apoptosis. Biochem Soc Trans 36: 1-9, 2008.
23. Li J and Yuan J: Caspases in apoptosis and beyond. Oncogene 27: 6194-6206, 2008.
24. Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 8: 286-298, 2007.